Fact-checked by Grok 2 weeks ago

Factor IX

Factor IX, also known as Christmas factor or coagulation factor IX, is a vitamin K-dependent serine protease zymogen that plays a central role in the intrinsic pathway of the blood coagulation cascade.^[1] Encoded by the F9 gene located on the long arm of the X chromosome at position Xq27.1, it is primarily synthesized in the liver as a single-chain glycoprotein consisting of 415 amino acids with a molecular weight of approximately 57 kDa, featuring distinct domains including Gla (γ-carboxyglutamic acid), two epidermal growth factor-like (EGF) domains, an activation peptide, and a catalytic serine protease domain.^[1]^[2] In its inactive form, Factor IX circulates in plasma at concentrations of 5 μg/mL (about 90 nM) and is activated to Factor IXa through proteolytic cleavage by either the tissue factor/factor VIIa complex or factor XIa, resulting in a two-chain molecule linked by a disulfide bond.^[2] The activated Factor IXa then forms the "tenase" complex with activated factor VIIIa (FVIIIa) on negatively charged phospholipid surfaces in the presence of calcium ions, dramatically amplifying its catalytic efficiency to activate factor X to factor Xa by over 1,000,000-fold, which subsequently converts prothrombin to thrombin and promotes fibrin clot formation to achieve hemostasis.^[2] This process is tightly regulated by inhibitors such as antithrombin, protein Z-dependent protease inhibitor (ZPI), and protease nexin-2 (PN2), as well as receptor-mediated clearance via the low-density lipoprotein receptor-related protein 1 (LRP1).^[2] Deficiency or dysfunction of Factor IX, often due to mutations in the F9 gene, results in hemophilia B (also called Christmas disease), an X-linked recessive bleeding disorder characterized by prolonged bleeding episodes, particularly into joints and muscles, affecting approximately 1 in 25,000–30,000 males worldwide.^[1]^[3] Treatment typically involves replacement therapy with plasma-derived or recombinant Factor IX concentrates to prevent or control bleeding, with advances including FDA-approved gene therapies such as etranacogene dezaparvovec (Hemgenix) in 2022 and approaches leveraging hyperactive variants like FIX-Padua to achieve sustained factor levels.^[3]^[2]^[4] Over 1,400 unique mutations in the F9 gene have been identified as of 2024, leading to a spectrum of severities from mild to severe, and the protein's vitamin K dependency underscores its sensitivity to anticoagulants like warfarin.^[1]^[5]^[2]

Structure and Biochemistry

Domain Architecture

Factor IX is a single-chain zymogen glycoprotein comprising 415 amino acids and exhibiting a molecular weight of approximately 55 kDa.^[6] This structure is synthesized in the liver as an inactive precursor, featuring a modular domain organization essential for its role in hemostasis. The protein includes an N-terminal gamma-carboxyglutamic acid (Gla) domain (residues 1–40), which facilitates binding to calcium ions and phospholipid membranes; two tandem epidermal growth factor-like (EGF) domains—EGF1 (residues 46–84) and EGF2 (residues 85–127)—that mediate specific protein-protein interactions; and a C-terminal serine protease domain (residues 181–415), which adopts a trypsin-like fold responsible for catalytic activity following zymogen activation.^[7]^[8] The Gla domain contains 12 gamma-carboxylated glutamic acid residues critical for metal ion coordination, while the EGF domains each bind one calcium ion, contributing to structural rigidity.^[9] Post-translational modifications are integral to Factor IX's functionality and stability. These include gamma-carboxylation of the 12 Gla residues in a vitamin K-dependent manner, N- and O-linked glycosylation at four sites (primarily Asn157, Asn167, and Asn262 for N-glycosylation, with additional O-glycosylation in the activation peptide), tyrosine sulfation at position 155, and multiple disulfide bonds—totaling 11 intra- and inter-domain linkages—that maintain the protein's compact conformation.^[10]^[11]^[8] The sulfation at Tyr155, located in the EGF1 domain, enhances binding affinity to cofactors, while the disulfide bridges, such as the interchain link between Cys132 and Cys289 in the activated form, prevent unfolding under physiological conditions. Glycosylation contributes to approximately 17% of the protein's mass and influences secretion and clearance. Structural studies have elucidated the atomic details of these domains through complementary techniques. Nuclear magnetic resonance (NMR) spectroscopy has revealed the dynamic, largely unstructured nature of the Gla domain in solution without calcium, transitioning to a compact helix-loop-helix fold upon metal binding.^[13] X-ray crystallography has provided high-resolution insights, including the EGF1 domain at 1.5 Å resolution, showcasing its beta-sheet core stabilized by a calcium-binding loop with six oxygen ligands from main-chain carbonyls and side chains.^[14] The EGF2 and protease domains have been crystallized as part of activated Factor IXa at resolutions up to 1.37 Å, highlighting the 110° interdomain angle between EGF modules and the active-site geometry featuring the catalytic triad His221-Asp269-Ser365.^[15] These structures underscore the evolutionary conservation of Factor IX across mammals, sharing approximately 80% sequence identity with mouse and 85-86% with dog orthologs, preserving key residues in the Gla and protease domains for functional equivalence.^[16]^[17]

Activation Mechanism

Factor IX, a zymogen serine protease, is primarily activated through limited proteolysis in two distinct pathways of the coagulation cascade. In the intrinsic pathway, Factor XIa initiates activation by cleaving the peptide bond after Arg^{145} (Arg^{145}-Ala^{146}), generating the intermediate Factor IXα, followed by cleavage after Arg^{180} (Arg^{180}-Val^{181}) to yield the fully active Factor IXaβ and release a 35-residue activation peptide (Ala^{146}-Arg^{180}).^[18]^[19] This sequential process is calcium-dependent, with the γ-carboxyglutamic acid (Gla) domain of Factor IX binding to a specific exosite on the A3 domain of Factor XIa, enhancing catalytic efficiency for the second cleavage by approximately sevenfold compared to the first.^[18] The reaction occurs in solution without requiring phospholipid surfaces, though platelet activation may facilitate it in vivo.^[20] In the extrinsic pathway, the complex of Factor VIIa and tissue factor similarly activates Factor IX by cleaving the same Arg^{145}-Ala^{146} and Arg^{180}-Val^{181} bonds, providing an alternative route for rapid initiation of coagulation upon vascular injury.^[21]^[22] This mechanism bypasses the contact activation steps and is particularly important for early thrombin burst generation.^[23] Activation induces structural rearrangements, separating the light chain (Gla and epidermal growth factor-like domains) from the heavy chain (protease domain) via disulfide linkage while exposing the catalytic triad (His^{221}, Asp^{269}, Ser^{365}) in the active site of the heavy chain.^[24]^[25] These allosteric changes transform the inactive zymogen into a functional enzyme, with the light chain facilitating membrane binding. The activated Factor IXa then assembles into the intrinsic tenase complex with Factor VIIIa on phospholipid surfaces (e.g., activated platelets), stabilized by calcium ions, which dramatically boosts its proteolytic activity toward Factor X.^[26] In this complex, kinetic parameters for Factor X activation include a K_m of approximately 0.2 μM and k_{cat} up to 20 s^{-1}, reflecting a million-fold enhancement over Factor IXa alone.^[27] Minor activation pathways include limited proteolysis by plasmin, which can cleave Factor IX at similar sites under fibrinolytic conditions, though this often leads to subsequent inactivation.^[28] Additionally, autoactivation of Factor IX occurs at high concentrations in vitro, potentially contributing to amplification in concentrated plasma environments.^[29] For recombinant Factor IX used in hemophilia B therapeutics, production systems must ensure efficient γ-carboxylation and sulfation/phosphorylation at key residues (e.g., Tyr^{155}, Ser^{158}) to yield activation-competent forms with near-native activity, as deficiencies reduce recovery by 1.5–2-fold compared to plasma-derived products.^[24] The EGF1 domain aids activation by mediating exosite interactions during cleavage.^[30]

Genetics

F9 Gene

The F9 gene, located on the long arm of the human X chromosome at cytogenetic band q27.1, spans approximately 34 kb of genomic DNA and consists of eight exons interrupted by seven introns. In the GRCh38.p14 human genome assembly, it occupies coordinates X:139,530,739-139,563,459 on the forward strand, encoding a primary transcript that produces a 461-amino-acid pre-pro-protein, including a 28-residue signal peptide and an 18-residue propeptide, which is processed to yield the mature 415-amino-acid Factor IX protein.^[1]^[31]^[32] The promoter region of F9 is regulated by hepatocyte nuclear factor 4 alpha (HNF4α), a key liver-enriched transcription factor that binds to specific motifs to drive expression, alongside other factors such as C/EBP that contribute to tissue-specific control. Expression of F9 is predominantly restricted to hepatocytes in the liver, where it achieves high transcript levels (RPKM 181.1), with minimal detection in other tissues, reflecting its role in hepatic synthesis of coagulation factors. The primary mRNA transcript measures about 2.8 kb, undergoes standard splicing to remove introns, and produces a main isoform, though alternative splicing yields at least two variants encoding slightly different proteins, with such events being rare in normal physiology.^[33]^[1]^[34] Evolutionarily, the F9 gene exhibits high conservation across vertebrates, with amino acid sequence homology reaching 83% between human and bovine Factor IX, and intron-exon boundaries largely preserved in mammalian orthologs, underscoring its ancient origin in the coagulation system. The gene was first cloned in 1982 through screening of a human liver cDNA library, yielding partial sequences that revealed the coding region, followed by publication of the full genomic sequence in 1984, which confirmed the eight-exon structure and enabled early studies of its expression.^[31]^[35]^[32] Biosynthesis of Factor IX begins with transcription of F9 in hepatocytes, followed by translation of the pre-pro-mRNA into the pre-pro-protein on endoplasmic reticulum ribosomes, where the signal peptide is cleaved co-translationally to produce pro-Factor IX. Post-translational modifications occur primarily in the endoplasmic reticulum, including γ-carboxylation of 12 glutamic acid residues to γ-carboxyglutamic acid (Gla) by the vitamin K-dependent γ-glutamyl carboxylase enzyme, which requires reduced vitamin K as a cofactor; the protein then traffics to the Golgi apparatus for additional processing, such as O-glycosylation and sulfation, before secretion into plasma.^[2]^[36]

Mutations and Inheritance

Factor IX deficiency, known as hemophilia B, follows an X-linked recessive inheritance pattern, where the F9 gene is located on the X chromosome. Males, being hemizygous for the X chromosome, express the mutant allele and typically manifest the disease if they inherit the defective gene from their carrier mother. Females, who are heterozygous carriers, generally have sufficient functional Factor IX from their normal X chromosome and remain asymptomatic, though they transmit the mutation to 50% of their sons (who will be affected) and 50% of their daughters (who will be carriers).^[31]^[37] The spectrum of genetic mutations in the F9 gene is diverse, with 1,692 unique pathogenic variants documented in comprehensive databases as of 2023. These include predominantly point mutations, accounting for approximately 73% of cases, with missense variants comprising the majority (around 58-66%) that alter amino acid sequences without abolishing protein production entirely. Nonsense mutations, which introduce premature stop codons, represent about 5-10%, while small deletions and insertions together make up roughly 15-20%, often leading to frameshifts and truncated proteins. Splice-site mutations, affecting about 8%, disrupt intron-exon boundaries and result in aberrant mRNA processing. Large gross deletions, occurring in 5-6% of cases, remove entire exons or the whole gene and are associated with severe phenotypes. The updated interactive F9 variant database, maintained by the Scientific and Standardization Committee (SSC) on Factor IX of the International Society on Thrombosis and Haemostasis (ISTH), serves as a key repository for these entries, facilitating genotype-phenotype correlations.^[38]^[39]^[40] Mutations in F9 can be classified based on their impact on circulating Factor IX protein levels and activity, distinguishing between cross-reacting material positive (CRM+) variants, where antigen levels are normal but functional activity is reduced due to qualitative defects, and CRM- variants, characterized by both low antigen and low activity from quantitative deficiencies like null alleles. CRM+ mutations often involve missense changes in critical domains, such as the activation peptide or catalytic site; for instance, the Arg145His substitution impairs proteolytic cleavage by Factor XIa or VIIa, preventing proper zymogen activation to the active enzyme. These distinctions are crucial for understanding disease severity and potential therapeutic responses.^[38]^[41] Approximately one-third of hemophilia B cases arise from de novo mutations in the F9 gene, with this rate higher in sporadic (non-familial) presentations compared to inherited ones, reflecting the elevated mutation rate in male germ cells. This phenomenon contributes significantly to the disease's incidence, independent of family history.^[37]^[42] In female carriers, detection of the mutation is complicated by X-chromosome inactivation, or Lyonization, a random process early in embryonic development that silences one X chromosome per cell, leading to mosaic expression and variable Factor IX levels (typically 20-80% of normal, but occasionally <20% in skewed cases, potentially causing mild symptoms). Carrier status is confirmed through genetic testing, including linkage analysis for familial cases or direct sequencing of the F9 gene for de novo or unknown variants; prenatal diagnosis employs similar methods, often via chorionic villus sampling or amniocentesis to assess fetal genotype.^[43]^[44] Historical efforts to model F9 mutations and explore therapeutic production included the 1997 generation of transgenic sheep expressing human Factor IX via nuclear transfer from transfected fetal fibroblasts, akin to the cloning of Dolly, which demonstrated the feasibility of large-scale recombinant protein production in milk for hemophilia B treatment.^[45]

Physiological Role

Coagulation Cascade Involvement

Factor IX serves as a key serine protease zymogen in the blood coagulation cascade, primarily within the intrinsic pathway, where it is activated by factor XIa following contact activation involving factors XII and XI. This activation occurs through proteolytic cleavages at Arg145-Ala146 and Arg180-Val181, converting factor IX to its active form, factor IXa.^[2] In the extrinsic pathway, factor IX can also be activated by the tissue factor/factor VIIa complex at sites of vascular injury, providing an alternative initiation route that bridges the two pathways.^[2] These activation mechanisms position factor IXa as a central amplifier in hemostasis, ensuring rapid progression toward clot formation upon endothelial disruption.^[46] Once activated, factor IXa assembles with its cofactor, activated factor VIIIa, and calcium ions on negatively charged phospholipid membranes—typically exposed on activated platelets—to form the intrinsic tenase complex. This complex dramatically enhances the activation of factor X to factor Xa, with the cofactor factor VIIIa accelerating factor IXa's catalytic efficiency by approximately 20,000-fold.^[2] The tenase complex amplifies factor X activation by over 1,000,000-fold compared to factor IXa alone, representing a critical rate-limiting step in the propagation phase of coagulation.^[2] Downstream, factor Xa then forms the prothrombinase complex with factor Va to convert prothrombin into thrombin, which cleaves fibrinogen to fibrin and activates additional cofactors, culminating in stable clot formation.^[2] In human plasma, factor IX circulates at a concentration of approximately 5 μg/mL (about 90 nM), with a half-life of 18–24 hours, ensuring availability for rapid response to injury.^[2] Hemostasis can be maintained with factor IX activity levels as low as 1–5% of normal (corresponding to moderate hemophilia B), though bleeding risks increase with trauma or surgery at these reduced levels.^[47] In vivo studies using factor IX knockout mice demonstrate severe bleeding phenotypes, such as prolonged tail bleeding leading to death without intervention, underscoring factor IX's essential role.^[48] Infusion of human factor IX restores hemostasis in these models, confirming its functional conservation across species.^[48]

Regulation and Inhibitors

Factor IX activity is primarily regulated by several natural inhibitors to maintain hemostatic balance and prevent excessive thrombosis. The main plasma inhibitor of activated Factor IX (FIXa) is antithrombin III (ATIII), which forms a 1:1 covalent complex with FIXa through a suicide substrate mechanism involving the reactive center loop of ATIII and the active site of FIXa.^[49] This inhibition proceeds slowly in the absence of cofactors, with a second-order rate constant of approximately 3.1 × 10³ M⁻¹ min⁻¹ (equivalent to ~5 × 10¹ M⁻¹ s⁻¹), limiting FIXa's contribution to the coagulation cascade under basal conditions.^[49] Heparin and related glycosaminoglycans, such as fondaparinux or unfractionated heparin, dramatically accelerate this process by inducing a conformational change in ATIII that enhances its reactivity toward FIXa by 60- to 80-fold, primarily through bridging interactions and exosite engagement on FIXa.^[49]^[2] The Protein C pathway provides indirect regulation of FIXa by targeting the intrinsic tenase complex, in which FIXa associates with activated Factor VIII (FVIIIa) on phospholipid surfaces to activate Factor X. Activated Protein C (APC), generated when thrombin binds thrombomodulin on endothelial cells, proteolytically inactivates FVIIIa in a reaction accelerated by its cofactor Protein S, thereby dismantling the tenase complex and curtailing FIXa-mediated amplification of coagulation.^[2] This mechanism is particularly important on endothelial surfaces, where Protein S enhances APC's specificity for FVIIIa cleavage at Arg336 and Arg562 sites, reducing tenase activity by over 90% under physiological conditions.^[2] Another specific inhibitor of FIXa is the Protein Z-dependent protease inhibitor (ZPI), a serpin that targets FIXa particularly when it is bound to phospholipid membranes in the tenase complex. ZPI, in complex with its cofactor Protein Z (a vitamin K-dependent protein), inhibits FIXa through a similar covalent mechanism to ATIII, but with enhanced efficiency on procoagulant surfaces due to Protein Z anchoring ZPI near FIXa.^[50] This inhibition is calcium- and phospholipid-dependent, downregulating FIXa activity in the factor Xase complex by forming a stable acyl-enzyme intermediate that prevents further substrate turnover.^[50] ZPI's role complements ATIII by providing localized control at sites of clot formation.^[2] Factor IX levels exhibit age-related changes, with plasma activity in newborns and infants typically at 20-50% of adult values due to immature hepatic synthesis.^[51] These levels progressively increase 2- to 3-fold, reaching adult ranges (50-150%) by around 6 months to 1 year of age and stabilizing by early adulthood (around age 20), reflecting developmental maturation of the coagulation system.^[51]^[52] Pathophysiological dysregulation of Factor IX regulation contributes to thrombophilia, where elevated FIX activity (>120%) is associated with increased risk of venous thrombosis. For instance, plasma FIX levels exceeding 130-150 IU/dL correlate with a twofold higher incidence of deep vein thrombosis, independent of other factors like FVIII, due to enhanced tenase complex formation and thrombin generation.^[53] Such elevations may arise from genetic variants or acquired conditions disrupting inhibitory controls like ATIII or ZPI.^[2]

Clinical Aspects

Hemophilia B

Hemophilia B, also known as factor IX deficiency or Christmas disease, is a rare X-linked recessive bleeding disorder characterized by insufficient levels of functional factor IX, leading to impaired blood clotting and a predisposition to prolonged bleeding episodes.^[47] It primarily affects males, with females serving as carriers, and manifests through a range of clinical severities depending on the residual factor IX activity in the blood.^[54] The condition arises from mutations in the F9 gene, as detailed in the genetics section, and has significant implications for affected individuals' quality of life due to recurrent hemorrhages.^[55] Epidemiologically, hemophilia B affects approximately 1 in 25,000 to 30,000 male births worldwide, representing about 15-20% of all hemophilia cases.^[37] The global prevalence is estimated at approximately 3.8 per 100,000 males, with around 45,600 diagnosed individuals as of 2024.^[56] The total number of people with hemophilia A and B combined is estimated to exceed 1 million globally, though significant underdiagnosis persists in low- and middle-income countries.^[56] Prevalence is notably higher in regions with elevated rates of consanguineous marriages, such as parts of the Middle East, North Africa, and South Asia, where inbreeding increases the likelihood of homozygous mutations in offspring.^[57] The disorder was first identified as distinct from hemophilia A in 1952, when researchers described it in a young patient named Stephen Christmas, using early coagulation assays that revealed differences in clotting factor responses during the 1950s.^[58] Severity is classified based on plasma factor IX activity levels: severe cases exhibit less than 1% activity and are prone to spontaneous bleeding; moderate cases have 1-5% activity with bleeds typically triggered by injury; and mild cases show 6-40% activity, where bleeding occurs mainly after mild trauma or surgery.^[37] Common symptoms include hemarthroses, or joint bleeds, most frequently affecting the knees, ankles, and elbows, which can lead to chronic pain and mobility issues if recurrent.^[54] Muscle hematomas, deep tissue bleeding causing swelling and compartment syndrome, are also prevalent, alongside a 3-5% risk of intracranial hemorrhage in neonates, often presenting as unexplained neurological symptoms shortly after birth.^[59] In chronic, inadequately managed cases, repeated hemorrhages may form pseudotumors—encapsulated cystic masses from organized blood clots that erode bone and soft tissue, mimicking neoplasms.^[60] Pathophysiologically, the deficiency reduces intrinsic tenase complex activity, where factor IXa, in complex with factor VIIIa, calcium, and phospholipids, normally activates factor X; this impairment hampers thrombin generation, prolonging the activated partial thromboplastin time (aPTT) and destabilizing fibrin clot formation.^[37] Complications include the development of alloantibodies (inhibitors) against factor IX in 1-3% of patients, particularly those with severe disease and certain genetic mutations, which neutralize replacement factors and exacerbate bleeding risk.^[61] Repeated joint bleeds also contribute to hemophilic arthropathy, a progressive degenerative joint disease involving synovitis, cartilage destruction, and bony overgrowth, often resulting in lifelong disability without preventive measures.^[62]

Diagnosis and Treatment

Diagnosis of Factor IX (FIX) deficiency, also known as hemophilia B, begins with laboratory assays to measure FIX activity levels in plasma, which classify the condition as severe (<1% activity), moderate (1-5%), or mild (5-40%). The one-stage clotting assay, based on activated partial thromboplastin time (aPTT), is the most widely used method globally, involving dilution of patient plasma with FIX-deficient plasma and comparison of clotting times to a calibrator curve.^[63] The chromogenic assay serves as an alternative or confirmatory test, particularly when the one-stage assay yields normal results despite clinical suspicion, by quantifying FIX through enzymatic generation of factor Xa and measurement of optical density changes.^[63] These functional assays guide initial diagnosis, often prompted by symptoms such as prolonged bleeding after injury or surgery. Genetic testing via next-generation sequencing of the F9 gene identifies causative mutations, including single nucleotide variants, insertions, deletions, and copy number variants, for definitive diagnosis and family counseling.^[64] Carrier testing for females uses the same DNA analysis to detect heterozygous mutations, enabling risk assessment for offspring.^[64] The primary treatment for hemophilia B is replacement therapy with FIX concentrates to restore hemostasis during bleeding episodes or prophylactically. Plasma-derived FIX products, such as prothrombin complex concentrates, provide effective replacement but carry a small risk of viral transmission despite purification processes.^[65] Recombinant FIX concentrates, preferred for their lower immunogenicity and viral safety, include standard half-life options like Benefix, approved by the FDA in 1997 for on-demand and prophylactic use.^[65] Extended half-life recombinant products, such as Alprolix (Fc fusion protein) and Idelvion (albumin fusion protein), extend FIX circulation, allowing dosing intervals of 7-14 days and reducing infusion frequency compared to standard products.^[65] Prophylaxis with regular FIX infusions is standard for severe hemophilia B to prevent spontaneous bleeds and joint damage, typically administered weekly at doses maintaining trough FIX activity above 1%.^[65] This approach achieves 80-90% reduction in annualized bleeding rates compared to on-demand therapy, with extended half-life products showing mean rates as low as 1.29 versus 3.12 for standard formulations.^[65] Gene therapy using adeno-associated virus (AAV) vectors represents a transformative one-time treatment, with etranacogene dezaparvovec (Hemgenix) approved by the FDA in 2022 and the European Commission in 2023 for adults with hemophilia B on FIX prophylaxis.^[66] As of 2025, four-year follow-up data from the phase 3 HOPE-B trial demonstrate sustained mean FIX activity of 37% in treated patients, with 94% remaining off prophylaxis and annualized bleeding rates reduced by approximately 90% (from 4.16 to 0.40).^[66] Challenges include transient elevations in liver enzymes in about 17% of patients, managed with corticosteroids, and potential preexisting immunity to AAV vectors limiting eligibility or necessitating redosing strategies.^[66] Emerging therapies aim to further simplify management and address limitations of current options. B-cell-mediated cell therapy, such as BE-101 using CRISPR/Cas9-engineered B cells to produce FIX, entered phase 1/2 trials in 2025 with the first patient dosed, showing potential for durable FIX expression without preconditioning chemotherapy.^[67] Non-factor therapies like fitusiran, an siRNA that reduces antithrombin III levels to enhance thrombin generation, received FDA approval in March 2025 for once-monthly subcutaneous prophylaxis in hemophilia B patients with or without inhibitors.^[68] Ongoing monitoring of therapy involves pharmacokinetic studies to assess FIX half-life, which is 18-24 hours for standard concentrates, guiding individualized dosing.^[69] Inhibitor development, occurring in 1-3% of patients, is screened using the Bethesda assay, which quantifies neutralizing antibodies by measuring residual FIX activity after incubation with patient plasma; titers ≥0.6 Bethesda units on two occasions confirm positivity.^[69]

References

[1]
2158 - Gene ResultF9 coagulation factor IX [ (human)] - NCBI
Sep 5, 2025 · This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen.
[2]
Blood Coagulation Factor IX: Structure, Function, and Regulation - NIH
May 22, 2025 · Blood coagulation factor IX plays a crucial role in the intrinsic pathway of coagulation by generating factor Xa, ultimately leading to thrombin formation.
[3]
Factor ix (intravenous route, injection route) - Side effects & dosage
May 1, 2025 · Factor IX is a protein produced naturally in the body. It helps the blood form clots to stop bleeding. Injections of factor IX are used to treat hemophilia B.
[4]
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-hemophilia-b
[5]
Structure-function relationships in factor IX and factor IXa - PubMed
Factor IX (FIX) consists of an N-terminal gamma-carboxyglutamic acid (Gla) domain followed by two epidermal growth factor (EGF)-like domains, and the C- ...Missing: architecture | Show results with:architecture
[6]
Coagulation factor IX analysis in bioreactor cell culture supernatant ...
Mar 23, 2021 · Immature FIX is composed of six structural domains: an N-terminal propeptide, the GLA domain, two consecutive EGF-like domains followed by a ...
[7]
US9233145B2 - Factor IX polypeptides and methods of use thereof
GLA: contains 12 γ-carboxylated glutamic acid (Gla) residues. ACT PEP: activation peptide cleaved to yield active protease. Other modifications: N- and O ...
[8]
Characterization of IXINITY® (Trenonacog Alfa), a Recombinant ...
Differential investigations from plasma-derived and recombinant factor IX revealed major differences in post-translational modifications of activation peptides.2. Methods · 2.8. Peptide Mapping · 3. Results
[9]
[PDF] Evaluation of the impact of the upstream bioprocess ... - UQ eSpace
2.2 Modulation of recombinant Factor IX post-translational modifications ... is the most heavily glycosylated region of Factor IX and also contains a sulfation at ...
[10]
Factor IX - an overview | ScienceDirect Topics
The final factor IX zymogen protein consists of 415 residues (Mr 57,000) and contains 17% carbohydrate by weight DiScipio et al (1978). ... Factor Xa is also ...
[11]
Crystal Structure of Mg2+- and Ca2+-bound Gla Domain of Factor IX ...
Resolution range (Å), 20-1.55, 20-1.80. Unique reflections, 39489, 27532 ... In the crystal structure of factor IX Gla domain in complex with IX-bp, 1-, 7 ...
[12]
The structure of a Ca2+-binding epidermal growth factor-like domain
We have determined, at high resolution (1.5 Å), the crystal structure of such a domain, from human clotting factor IX, as a complex with Ca 2+.
[13]
6MV4: CRYSTAL STRUCTURE OF HUMAN COAGULATION ...
Feb 20, 2019 · Activated coagulation factor IX (FIXa) consists of a γ-carboxyglutamic acid domain, two epidermal growth factor-like (EGF) domains, and a C-terminal protease ...Missing: NMR | Show results with:NMR
[14]
Identification of coagulation factor IX variants with enhanced activity ...
Aug 27, 2021 · In the current study, we resurrected a panel of ancient mammalian coagulation factor IX (FIX) variants with the goal of identifying improved ...
[15]
Mini-review on “A novel one-step purification of mouse factor IX” - PMC
This result is impressive, given a 82% sequence similarity between mouse and human factor IX. Importantly, human and murine FIX interact with the same proteins ...
[16]
The Mechanism Underlying Activation of Factor IX by Factor XIa - PMC
The serine protease factor XIa (fXIa) contributes to blood clot formation at a wound site primarily by converting factor IX (fIX) to the protease fIXaβ.
[17]
Cleavage at Arginine 145 in Human Blood Coagulation Factor IX ...
For this purpose, the activation intermediate factors IXα and IXaα were purified after cleavage of the Arg145-Ala146 and Arg180-Val181 bonds, respectively.
[18]
Activation of human factor IX (Christmas factor) - PMC - NIH
Factor IX is activated by Factor XIa in the presence of calcium, cleaving two internal peptide bonds, releasing an activation peptide and forming Factor ...
[19]
Activation of factor IX by the reaction product of tissue factor ... - PNAS
The reaction product of tissue factor and Factor VII functioned as a potent Factor IX activator in the assay system used.
[20]
Independence of Factor XIa Subunits in Factor IX Activation. | Blood
Nov 16, 2006 · Both FXIa and FVIIa/TF activate FIX by proteolytic cleavage at Arg145-Ala146 and Arg180-Val181 to generate FIXaβ, and release an 11 kDa ...
[21]
Activation of factor IX by the reaction product of tissue factor ... - NIH
The reaction product of tissue factor and Factor VII functioned as a potent Factor IX activator in the assay system used.
[22]
Coagulation Factor IX for Hemophilia B Therapy - PMC - NIH
Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B.
[23]
Probing activation‐driven changes in coagulation factor IX by mass ...
Activated Factor IX (FIXa) is a poor enzyme that needs factor VIII‐driven stabilization for efficient catalysis. Mass spectrometry reveals that the protease ...
[24]
Biochemistry, Clotting Factors - StatPearls - NCBI Bookshelf - NIH
Feb 24, 2023 · Clotting factor IX is a serine protease within the intrinsic pathway. Although IXa is in its active form, IXa enzyme efficiency is abysmal ...
[25]
Kinetics of coagulation factor X activation by platelet-bound factor IXa
A detailed kinetic analysis of the effects of platelets, phospholipids, and factor VIII on factor IXa catalyzed factor X activation was done.
[26]
Proteolytic processing of human coagulation factor IX by plasmin
11 Conversely, plasmin has been shown in vitro to inactivate factor (F.) IX,12 activate F. VII13 and F. XII,14 and initially activate and then subsequently ...
[27]
Activation of factor IX by factor XIa - PubMed
A large amount of new evidence now indicates that factor IX activation by factor XIa occurs on the surface of activated platelets.
[28]
Blood Coagulation Factor IX: Structure, Function, and Regulation
May 22, 2025 · In addition, EGF1 appears to mediate binding to the tissue factor–factor VIIa ... Rapaport, “Activation of Factor IX by the Reaction Product of ...
[29]
Entry - *300746 - COAGULATION FACTOR IX; F9 - (OMIM.ORG)
The F9 gene encodes coagulation factor IX, which circulates as an inactive zymogen until proteolytic release of its activation peptide.
[30]
https://iubmb.onlinelibrary.wiley.com/doi/full/10.1002/iub.70024
[31]
MiRNA-Based Regulation of Hemostatic Factors through Hepatic ...
May 2, 2016 · HNF4α has a direct and important role in the regulation of multiple hepatic coagulation genes. ... F9, F11, F12, SERPINC1, PROC, and PROS1 ...Missing: HNF4 | Show results with:HNF4
[32]
https://pubmed.ncbi.nlm.nih.gov/6329734
[33]
Isolation and characterization of a cDNA coding for human factor IX
A cDNA library prepared from human liver has been screened for factor IX (Christmas factor), a clotting factor that participates in the middle phase of ...Missing: F9 cloning history 1984
[34]
Gamma-carboxylation of protein precursors - Reactome
A single enzyme, vitamin K-dependent gamma-carboxylase, catalyzes the gamma-carboxylation of all eight proteins involved in clotting.
[35]
Hemophilia B (Factor IX Deficiency) - Medscape Reference
Apr 30, 2025 · More than 1000 mutations with different amino acid substitutes have been described in hemophilia B.
[36]
The CDC Hemophilia B mutation project mutation list - NIH
The frequencies of the nine mutation types are outlined in Table 1. The most common mutation in F9 was missense, which accounted for 58.4%. A smaller percentage ...
[37]
F9 missense variant hot spots associated with qualitative protein ...
Genotype and laboratory data from the EAHAD F9 Coagulation Factor Variant Database were extracted for genotype-phenotype analysis.19 The initial database ...
[38]
Molecular defects of factor IX Chicago-2 (Arg 145----His) and ...
Jul 1, 1989 · These mutations, each occurring at arginines, are identical to those in factor IX Chapel Hill and prothrombin Barcelona. These results suggest ...
[39]
A Cause of Hemophilia Manifestation in Carrier Females - PMC - NIH
Oct 28, 2020 · Lyonization is a process by which one of two X chromosomes in a female randomly becomes inactivated, forming a bar body early during fetal life; ...
[40]
A new hemophilia carrier nomenclature to define hemophilia in ...
Due to lyonization, a random interindividual X‐linked inactivation process, median plasma factor VIII/IX (FVIII/IX) levels of hemophilia carriers (HCs) are 0. ...
[41]
Human factor IX transgenic sheep produced by transfer of nuclei ...
Six transgenic lambs were liveborn: Three produced from cloned cells contained factor IX and neo transgenes, whereas three produced from the uncloned population ...
[42]
Coagulation factor IXa binding to activated platelets and ... - PubMed
Factor IX plays a central role in blood coagulation, since it can be activated by either XIa (intrinsic pathway) or tissue factor-VIIa (extrinsic pathway).
[43]
Hemophilia B - StatPearls - NCBI Bookshelf
Oct 29, 2023 · The genetic defect can occur either through X-linked inheritance or a spontaneous de novo mutation. Although this condition predominantly ...Continuing Education Activity · Introduction · Evaluation · Treatment / Management
[44]
A factor IX-deficient mouse model for hemophilia B gene therapy - NIH
Factor IX-Deficient Mice Are Hemophilic. The factor IX-deficient mice show extensive bleeding after clipping a portion of the tail and bleed to death unless ...Missing: knockout | Show results with:knockout
[45]
https://pubmed.ncbi.nlm.nih.gov/9405350/
[46]
Down-regulation of Factor IXa in the Factor Xase Complex by ...
Protein Z-dependent protease inhibitor (ZPI) is a serpin inhibitor of coagulation factor (F) Xa dependent on protein Z, Ca2+, and phospholipids.
[47]
Protease-activated Receptor Signaling by Coagulation ... - NIH
Thrombin activation of cell surface PAR1 up-regulates the expression of various cytokines (i.e., IL-1, IL-6 and TNF-α) and cell adhesion molecules; E-selectin, ...
[48]
Coagulation Factor IX Activity Assay, Plasma
Reference Values. ≤6 months: Normal, full-term newborn infants or healthy premature infants may have decreased levels (≥20%), which may not reach adult levels ...
[49]
Age-dependent effect on the level of factor IX - PubMed
Levels of factor IX:C were lowest in prepubertal subjects, then reached a plateau in early adult life with a secondary increase in later adult life (> 45 years) ...Missing: 2-3 fold
[50]
Blood Clotting Factor 9 - an overview | ScienceDirect Topics
Factor IX Protein. FIX is synthesized exclusively in hepatocytes and circulates in plasma at a concentration of approximately 5 µg/mL (90 nM). The mature ...
[51]
Hemophilia B - Symptoms, Causes, Treatment | NORD
Oct 15, 2024 · Hemophilia B is classified as mild, moderate or severe based upon the activity level of factor IX. In mild cases, bleeding symptoms may ...
[52]
Hemophilia B - GeneReviews® - NCBI Bookshelf
Aug 7, 2025 · Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery.
[53]
Changes over the last two decades in Hemophilia A and B ...
The global prevalence of HA is estimated to be 6.6–12.8 per 100,000. The global prevalence of HB is estimated at 1.2–2.7 per 100,000. In Italy, the prevalence ...Missing: worldwide | Show results with:worldwide
[54]
Consanguineous Marriage and Its Association With Genetic ... - NIH
Feb 9, 2024 · Both race and consanguinity have been identified as influencing factors in the prevalence of RBDs [66]. Consanguineous marriages, which are ...
[55]
Past, present and future of hemophilia: a narrative review - PMC
May 2, 2012 · Hemophilia B was distinguished from the more common hemophilia A in 1952, and was often referred to as "Christmas disease" after the last ...
[56]
Intracranial haemorrhage in haemophilia A and B - PubMed
Intracranial haemorrhage (ICH) during the neonatal period affects 3.5-4.0% of all haemophilia boys, which is considerably (40-80 times) higher than expected in ...
[57]
Hemophilic Pseudotumors: Diagnosis and Management - PMC - NIH
The main problem for patients with hemophilia is that they suffer from hemorrhages in the musculoskeletal system, both joints (hemarthrosis) and muscles. These ...
[58]
The prevalence and risk factors of inhibitor development of FVIII in ...
Inhibitors develop in approximately 30% of patients with hemophilia A (HA) and 1–3% of those with hemophilia B. Most inhibitors develop in patients with severe ...
[59]
Hemophilia and Hemorrhagic Arthropathy | PM&R KnowledgeNow
Jul 13, 2023 · Hemophilic arthropathy refers to persistent joint disease caused by multiple bleeds within one or more joints leading to decreased function, chronic pain, and ...
[60]
Factor VIII and Factor IX Activity Measurements for Hemophilia ... - NIH
The X-linked, hemostatic disorders of hemophilia are caused by the absence or reduction of clotting factor VIII (hemophilia A, HA) or factor IX (hemophilia B, ...
[61]
630373: Factor IX (Hemophilia B) Genetic Analysis - Labcorp
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
[62]
Hemophilia B (Factor IX Deficiency) Treatment & Management
Apr 30, 2025 · The treatment of hemophilia may involve management of hemostasis, management of bleeding episodes, use of factor replacement products and medications.
[63]
CSL Behring's Gene Therapy HEMGENIX® (etranacogene ...
Feb 7, 2025 · Approved in 2022 by the U.S. Food and Drug Administration (FDA), HEMGENIX is the first gene therapy for the treatment of adults with hemophilia ...
[64]
First Patient Treated in Hemophilia B Cell Therapy Trial | NBDF
Jul 30, 2025 · “BE-101 has the potential to be an important new therapeutic option in hemophilia B by delivering sustained FIX levels and durable bleed ...Missing: fitusiran siRNA ATIII
[65]
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic ...
Mar 28, 2025 · Qfitlia becomes the sixth Alnylam-discovered RNAi therapeutic approved by US FDA and first and only to treat hemophilia A or B with or without inhibitors.Missing: editing ATIII
[66]
[PDF] INHIBITORS IN HEMOPHILIA: A PRIMER - WFH
For patients with hemophilia B, the risk of inhibitor development is about 1-5% and is almost only seen in patients with severe hemophilia B in whom the hemo-.